Brian Weinstein
Stock Analyst at William Blair
(0.36)
# 4,273
Out of 5,182 analysts
12
Total ratings
28.57%
Success rate
-16.86%
Average return
Main Sectors:
Stocks Rated by Brian Weinstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDSX Biodesix | Upgrades: Outperform | n/a | $14.53 | - | 3 | Feb 27, 2026 | |
| BDX Becton, Dickinson and Company | Downgrades: Market Perform | n/a | $154.96 | - | 1 | May 1, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | n/a | $21.82 | - | 2 | Jul 15, 2022 | |
| GKOS Glaukos | Upgrades: Outperform | n/a | $115.06 | - | 3 | Feb 3, 2022 | |
| SERA Sera Prognostics | Initiates: Outperform | n/a | $2.16 | - | 1 | Aug 9, 2021 | |
| QDEL QuidelOrtho | Upgrades: Outperform | n/a | $14.98 | - | 2 | Jul 18, 2017 |
Biodesix
Feb 27, 2026
Upgrades: Outperform
Price Target: n/a
Current: $14.53
Upside: -
Becton, Dickinson and Company
May 1, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $154.96
Upside: -
10x Genomics
Jul 15, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $21.82
Upside: -
Glaukos
Feb 3, 2022
Upgrades: Outperform
Price Target: n/a
Current: $115.06
Upside: -
Sera Prognostics
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.16
Upside: -
QuidelOrtho
Jul 18, 2017
Upgrades: Outperform
Price Target: n/a
Current: $14.98
Upside: -